Showing 7571-7580 of 8194 results for "".
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- FDA Approves Juvederm® Ultra XC for Use in Lipshttps://practicaldermatology.com/news/fda-approves-juvederm-ultra-xc-for-use-in-lips/2458860/Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation
- Curology Launches Online Service For Customized Prescription Skincarehttps://practicaldermatology.com/news/curology-launches-online-service-for-customized-prescription-skincare/2458862/Curology launched a first-of-its-kind online service that offers customized prescription creams for acne and anti-aging. Founded by dermatologist Dr. David Lortscher, Curology partners patients with licensed healthcare professionals and custom-formulates medications at its laboratory in San Diego
- Ferndale Healthcare Launches Vegetarian Formula of Heliocarehttps://practicaldermatology.com/news/ferndale-healthcare-launches-vegetarian-formula-of-heliocare/2458868/Ferndale Healthcare® has introduced to its existing Heliocare® line a new vegetarian formula, free of gluten and artificial dyes. The new Heliocare® Ultra Dietary Supplement contains a powerful blend of antioxidants, including Fernblock®
- Solta Medical Launches Clear + Brilliant pelo for Laser Hair Removalhttps://practicaldermatology.com/news/solta-medical-launches-clear-brilliant-pelo-for-laser-hair-removal/2458875/Solta Medical, a division of Valeant Pharmaceuticals North America LLC launched its Clear + Brilliant pelo™ laser for permanent hair reduction. The US launch of this device, which joins Solta Medical's aesthetic device portfolio, follows a unique partnership with German Medical
- FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-approves-humira-for-moderate-to-severe-hidradenitis-suppurativa/2458873/The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults with HS. Earlier this year, the FDA granted HUMIRA orphan drug designation for t
- Alphaeon Launches Social Commerce Store for Physician Specialistshttps://practicaldermatology.com/news/alphaeon-launches-social-commerce-store-for-physician-specialists/2458876/ALPHAEON Corporation launched ShoutMD 3.0. ShoutMD is a unique professional and social network that allows board certified physician specialists to share insights, start discussions, and collaborate with their peers with the goal of improving patient experiences and outcomes, according to the com
- FDA Issues Consumer Update about Injectable Skin Lightening Productshttps://practicaldermatology.com/news/fda-issues-consumer-update-about-injectable-skin-lightening-products/2458879/A consumer update from the FDA warns that injectable skin lightening products are unapproved, untested drugs that could potentially cause harm. The FDA adds that it has not approved any injectable drugs for skin whitening or lightening. “These products pose a potentially significant
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev